Specific Immunoassays for Detection of Intact and Cleaved Forms of the Urokinase Receptor
Open Access
- 1 November 2004
- journal article
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 50 (11), 2059-2068
- https://doi.org/10.1373/clinchem.2004.038232
Abstract
Background: The cell surface receptor (uPAR) for urokinase plasminogen activator (uPA) is a strong prognostic marker in several types of cancer. uPA cleaves the three-domain protein uPAR(I-III) into two fragments: uPAR(I), which contains domain I; and uPAR(II-III), which contains domains II and III. Established immunoassays measure a combination of uPAR forms. Our aim was to design immunoassays for specific quantification of the individual forms of uPAR. Methods: Using appropriate combinations of epitope-mapped monoclonal antibodies (Mabs) for capture and europium-labeled detection Mabs, we designed two-site sandwich time-resolved fluorescence immunoassays (TR-FIAs): TR-FIA 1 to measure uPAR(I-III) alone; TR-FIA 2 to measure both uPAR(I-III) and uPAR(II-III); and TR-FIA 3 to measure uPAR(I). To avoid detection of uPAR(I-III) in TR-FIA 3, we used a combination of the peptide uPAR antagonist AE120 and a domain I antibody, R3. AE120 blocks the binding of R3 to uPAR(I-III). In contrast, AE120 does not interact with liberated domain I and therefore does not interfere with the binding of R3 to uPAR(I). Results: The limits of quantification (CV <20%) determined by adding the proteins to uPAR-depleted plasma were <3 pmol/L in all three assays. The interassay CVs in plasma with added analytes were <11%, and recoveries were between 93% and 105%. Cross-reactivities of purified proteins in the three TR-FIAs were no more than 4%. Studies on chymotrypsin cleavage of uPAR and size-exclusion chromatography of plasma with and without added protein further supported the specificity of the assays. Conclusions: The three novel TR-FIAs accurately quantify uPAR(I-III) alone, uPAR(I-III) together with uPAR(II-III), and uPAR(I), respectively, in biological samples, including plasma, and thus are well suited for studies of the diagnostic and prognostic value of individual uPAR forms in cancer patients.Keywords
This publication has 24 references indexed in Scilit:
- Proteolytic Regulation of the Urokinase Receptor/CD87 on Monocytic Cells by Neutrophil Elastase and Cathepsin GPublished by The American Association of Immunologists ,2004
- Structure-Function Relationships in the Interaction Between the Urokinase- Type Plasminogen Activator and Its ReceptorCurrent Pharmaceutical Design, 2003
- Cellular glycosylphosphatidylinositol-specific phospholipase D regulates urokinase receptor shedding and cell surface expressionJournal of Cellular Physiology, 1999
- The intact urokinase receptor is required for efficient vitronectin binding: receptor cleavage prevents ligand interactionFEBS Letters, 1997
- Cell‐Surface Acceleration of Urokinase‐Catalyzed Receptor CleavageEuropean Journal of Biochemistry, 1997
- Domain Interplay in the Urokinase ReceptorJournal of Biological Chemistry, 1996
- The receptor for urokinase plasminogen activator is present in plasma from healthy donors and elevated in patients with paroxysmal nocturnal haemoglobinuriaBritish Journal of Haematology, 1995
- A cleaved form of the receptor for urokinase‐type plasminogen activator in invasive transplanted human and murine tumorsInternational Journal of Cancer, 1994
- Ligand Interaction between Urokinase-Type Plasminogen Activator and Its Receptor Probed with 8-Anilino-1-naphthalenesulfonate. Evidence for a Hydrophobic Binding Site Exposed Only on the Intact ReceptorBiochemistry, 1994
- Activation of pro-urokinase and plasminogen on human sarcoma cells: a proteolytic system with surface-bound reactants.The Journal of cell biology, 1989